Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Crinetics Pharmaceuticals Inc CRNX

Healthcare Biotechnology
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid... see more

Recent & Breaking News (NDAQ:CRNX)

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 10, 2022

Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism

GlobeNewswire October 6, 2022

Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer

GlobeNewswire October 3, 2022

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 12, 2022

Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 8, 2022

New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly

GlobeNewswire September 6, 2022

New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and Metabolism

GlobeNewswire September 2, 2022

Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire August 12, 2022

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 10, 2022

Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology

GlobeNewswire August 4, 2022

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 12, 2022

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 10, 2022

Crinetics Presents Clinical and Research Results at ENDO 2022

GlobeNewswire June 8, 2022

Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

GlobeNewswire June 7, 2022

Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts

GlobeNewswire May 25, 2022

Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 12, 2022

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 10, 2022

Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering

GlobeNewswire April 18, 2022

Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering

GlobeNewswire April 12, 2022

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 11, 2022